Controlled Substances—Uses and Effects

Total Page:16

File Type:pdf, Size:1020Kb

Controlled Substances—Uses and Effects U.S. Department of Justice, Drug Enforcement Ad min is tra tion Controlled Substances—Uses and Effects Dependence ClassClass* * TTrade rade or Other NameNames s Medical UseUses s (Physical/Psycho.(Physical/Psycho.) ) NARCOTICS NARCOTIC S Opium II III V Dovers powder, Paregoric, Analgesic, antidiarrheal High High Morphine II III Morphine, Analgesic, antitussive High High MS-Contin, Roxanol, Roxanol-SR Codeine II III V Tylenol w/Codeine, Analgesic, antitussive Mod. Mod. Empirin w/Codeine, Robitussan A-C, Fiorinal w/Codeine Heroin I Diacetylmorphine, Horse, None High High Smack Hydro- II Dilaudid Analgesic High High morphone Meperidine II Demerol, Mepergan Analgesic High High (Pethidine) Methadone II Dolophine, Methadone, Analgesic High High-low Methadose Other I II III Numorphan, Percodan, Analgesic, antidiarrheal, High-low High-low narcotics IV V Percocet, Tylox, antitussive Tussionex, Fentanyl, Darvon, Lomotil, Talwin DEPRESSANTS DEPRESSANTS Chloral IV Noctec Hypnotic Mod. Mod. Hydrate Barbiturates II III IV Amytal, Butisol, Fiorinal, Anasthetic, High-mod. High-mod. Lotusate, Nembutal, anticonvulsant, Seconal, Tuinal, Phenobarbital sedative, hypnotic, veterinary euthanasia agent Benzodiazepines IV Ativan, Dalmane, Diazepam, Antianxiety, Low Low Librium, Xanax, Serax, Valium, anticonvulsant, sedative, Tranxexe, Verstran, Versed, hypnotic Halcion, Paxipam, Restoril Methaqualone I Quaalude Sedative, hypnotic High High Glutethimide III Doriden Sedative, hypnotic High Mod. Other depressants III IV Equanil, Miltown, Noludar, Antianxiety, sedative, Mod. Mod. Placidyl, Valmid hypnotic STIMULANTS STIMULANTS Cocaine II Coke, Flake, Snow, Crack Local anesthetic Possible High Amphetamines II Biphetamine, Delcobese, Attention defi cit disorders, Possible High Desoxyn, Dexedrine, narcolepsy, weight control Obetrol Phenmetrazine II Preludin Weight control Possible High Methylphenidate II Ritalin Attention defi cit disorders, Possible Mod. narcolepsy Other stimulants III IV Adipex, Cylert, Didrex, Weight control Possible High Ionamin, Melfi at, Plegine, Sanorex, Tenuate, Tepanil, Prelu-2 HALLUCINOGENS HALLUCINOGENS LSD I Acid, Microdot None None Unknown Mescaline, Peyote I Mexc, Buttons, Cactus None None Unknown Amphetamine I 2.5-DMA, PMA, STP, MDA, None Unknown Unknown variants MDMA, TMA, DOM, DOB Phencyclidine II PCP, Angel Dust, Hog None Unknown High Phencyclidine I PCE, PCPy, TCP None Unknown High analogues ` Other I Bufotenine, Iogaine, DMT, None None Unknown hallucinogens DET, Psilocybin, Psitocyn CANNABIS CANNABIS Marijuana I Pot, Acapulco Gold, Grass, None Unknown Mod. Reefer, Sinsemilla, Thai Sticks Tetrahydro- I II THC, Marinol Cancer chemotherapy, Unknown Mod. cannabinol antinauseant Hashish I Hash None Unknown Mod. Hashish oil I Hash Oil None Unknown Mod. * “Class” refers to one of the fi ve schedules of controlled substances established by the federal Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended 21 U.S.C. Section 801 and following. Duration Usual Method Possible Effects of With draw al Tolerance Hours of Ad min is tra tion Effects Overdose Syndrome NARCOTICS NARCOTICSNARCOTICS NARCOTICS Yes 3–6 Oral, smoked Euphoria, Slow and Watery eyes, Yes 3–6 Oral, smoked, injected drowsiness, shallow runny nose, respiratoryr e s p i r a t o r y breathing,b r e a t h i n g, yawning, depression,d e p r e s s i o n , clammyc la m m y skin,skin, loss of appetite, Yes 3–6 Oral, injected constricted convulsions, irritability pupils,p u p i ls , coma,c o m a , possiblep ossible tremors, panic, nausea death cramps, nausea chills,c h i l l s , sweatings w e a t i n g Yes 3–6 Injected,I n je c t e d , sniffed,s n i f f e d , smokeds m o k e d Yes 3–6 Oral,O r a l , injectedi n j e c t e d Yes 3–6 Oral,O r a l , injectedi n j e c t e d Yes 12–24 Oral,O r a l , injectedi n j e c t e d Yes Varies Oral, injected DEPRESSANTS DEPRESSANTS DEPRESSANTS Yes 5–8 Oral Slurred Shallow Anxiety, in som nia, speech,s p e e c h , respiration,r e s p i r a t ion, tremors, Yes 1–16 Oral disorientation, clammy skin, delirium, drunken dilatedd il a t e d pupils,p upils, convulsions, behavior weak and possible death without odor rapidr a p i d pulse,p u lse, Yes 4–8 Oral of alcohol coma, possible death Yes 4–8 Oral Yes 4–8 Oral Yes 4–8 Oral STIMULANTS STIMULANTS STIMULANTS Yes 1–2 Sniffed, smoked, injected Increased Agitation, Apathy, long Yes 2–4 Oral, injected alertness, increase in periods of excitation,e x c i t a t i o n , bodyb o d y temp.,t e m p., sleep, irritability, euphoria,e u p h o r i a , hallucinations,h a ll u c i n ations, depression, Yes 2–4 Oral, injected increased convulsions, disorientation Yes 2–4 Oral,O r a l , injectedinjected pulse rate & possible death bloodb l o o d pressure,p r e s s u r e , Yes 2–4 Oral,O r a l , injectedinjected insomnia, loss ofo f appetitea p p e t i t e HALLUCINOGENS HALLUCINOGENS HALLUCINOGENS Yes 8–12 Oral Illusions and Longer and Withdrawal Yes 8–12 Oral hallucinations, intense “trip” syndrome not Yes Varies Oral,O r a l , injectedi n j e c t e d poorp o o r episodes,e p is o d e s , reportedr e p o r t ed perception psychosis, Yes DaysD a y s Smoked,S m o ked, oral,oral, injectedinjected of time and possible death Yes DaysD a y s Smoked,S m o ked, oral,oral, injectedinjected distance Possible Varies Smoked,S m o ked, oral,oral, injectedinjected CANNABIS CANNABIS CANNABIS Yes 2–4 Smoked, oral Euphoria, Fatigue, Insomnia, relaxed paranoia,p a r a n o i a , hyperactivity Yes 2–4 Smoked, oral inhibitions, possible and decreased increased psychosisp s y c h o s is appetite Yes 2–4 Smoked,S m o k e d , oralo r a l appetite, Yes 2–4 Smoked, oral disorientated behavior .
Recommended publications
  • What's the Best First Line Anticonvulsant?
    What’s the best first line anticonvulsant? Stephen Hanson, DVM, MS, Dip. ACVIM (Neurology) Recurring seizure activity is a relatively common problem in canine patients. Nowadays, there are several good options for medical treatment, which makes the choice of which drug to use a little more complicated. All anticonvulsant drugs have advantages and disadvantages, so the selection of a first-line drug should be tailored for the individual patient and client. Phenobarbital: This has been the standard first choice drug for decades. The nice thing about Phenobarbital is that it works fairly well, controlling seizures in about 70% of dogs with epilepsy. Also, it is inexpensive and readily available. The biggest down-sides are its induction of hepatic metabolism and the need for frequent upward dose adjustments, as well as its potential to cause hepatotoxicity. The potential for liver disease increases with time, so a 2 year old dog placed on this medication is more likely to develop hepatotoxicity in his life-time than a 10 year old dog. Phenobarbital can also cause sedation and ataxia. While this is usually mild/transient, it can be a real problem in dogs with other pre- existing signs of intracranial disease. Polyuria, polydipsia and polyphagia are other common side effects. These signs vary widely in severity between patients. Pros: cheap, available at any corner pharmacy, works well Cons: higher doses required with time, possible serious liver side-effects Good first-line choice for middle-aged to older dogs without any pre-existing liver issues Poor choice for dogs with liver disease, dogs with other intracranial signs Questionable choice for young epileptic dogs Potassium/sodium bromide: This was the most commonly-used add on anticonvulsant drug for a long time.
    [Show full text]
  • Quest Diagnostics Prescription Drug Monitoring Reference Guide
    Clinical Drug Monitoring Reference Guide Clinical Drug Monitoring Test List with Test Codes Drug Class P P,D,M P,D D,M D Drug Class P P,D,M P,D D,M D Drug Class P P,D,M P,D D,M D Alcohol Metabolites 90079 16910 92142 16217 Cocaine Metabolite 92225 70248 16888 90082 16916 Naltrexone 93753 Amphetamines 92222 70245 16885 70209 16913 Eszopiclone 91251 Opiates 92230 18991 16891 70237* 16298* Amphetamines Fentanyl 36278 36279 36280 18996 16900 Oxycodone 92231 18992 16892 70238 16920 91590 91589 92484 92483 with Reflex d/l Isomers Gabapentin 70205 16904 Phencyclidine 92232 18993 16893 90083 16921 Antidepressants (urine) 94032 Heroin Metabolite 92226 90081 16911 90333 90329 Pregabalin 70208 16908 Antidepressants (serum) 94031 Marijuana Metabolite 92227 18989 16889 70233 16917 Propoxyphene 92233 18995 16894 70239 16922 Antipsychotics (urine) 94528 MDMA/MDA 92228 90078 16909 90334 90331 Synthetic Cannabinoids 93027 Antipsychotics (serum) 94529 Meperidine 70206 16905 Synthetic Stimulants 90322 Barbiturates 92223 70246 16886 70230 16912 Methadone Metabolite 92229 18990 16890 70234 16918 Tapentadol 90244 90243 Benzodiazepines 92224 70247 16887 70231 16914 Methamphetamine Tramadol 70207 16906 90319 Buprenorphine 16207 70249 16901 18998 16213 d/l Isomers Tricyclic Antidepressants 70204 16903 Buprenorphine 93093 93094 Methylphenidate 90247 90246 with Naloxone Zolpidem 91258 Mitragynine 39241 39240 Carisoprodol 18999 16902 *Includes oxycodone drug class Test Profiles Profile Name Base Profile Profile 1 Profile 2 Profile 3 Profile 4 Profile 5 Profile 6
    [Show full text]
  • Chapter 25 Mechanisms of Action of Antiepileptic Drugs
    Chapter 25 Mechanisms of action of antiepileptic drugs GRAEME J. SILLS Department of Molecular and Clinical Pharmacology, University of Liverpool _________________________________________________________________________ Introduction The serendipitous discovery of the anticonvulsant properties of phenobarbital in 1912 marked the foundation of the modern pharmacotherapy of epilepsy. The subsequent 70 years saw the introduction of phenytoin, ethosuximide, carbamazepine, sodium valproate and a range of benzodiazepines. Collectively, these compounds have come to be regarded as the ‘established’ antiepileptic drugs (AEDs). A concerted period of development of drugs for epilepsy throughout the 1980s and 1990s has resulted (to date) in 16 new agents being licensed as add-on treatment for difficult-to-control adult and/or paediatric epilepsy, with some becoming available as monotherapy for newly diagnosed patients. Together, these have become known as the ‘modern’ AEDs. Throughout this period of unprecedented drug development, there have also been considerable advances in our understanding of how antiepileptic agents exert their effects at the cellular level. AEDs are neither preventive nor curative and are employed solely as a means of controlling symptoms (i.e. suppression of seizures). Recurrent seizure activity is the manifestation of an intermittent and excessive hyperexcitability of the nervous system and, while the pharmacological minutiae of currently marketed AEDs remain to be completely unravelled, these agents essentially redress the balance between neuronal excitation and inhibition. Three major classes of mechanism are recognised: modulation of voltage-gated ion channels; enhancement of gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission; and attenuation of glutamate-mediated excitatory neurotransmission. The principal pharmacological targets of currently available AEDs are highlighted in Table 1 and discussed further below.
    [Show full text]
  • Definition of Controlled Substance Schedules
    UPDATED MARCH 2018 DEFINITION OF CONTROLLED SUBSTANCE SCHEDULES Drugs and other substances that are considered controlled substances under the Controlled Substances Act (CSA) are divided into five schedules. An updated and complete list of the schedules is published annually in Title 21 Code of Federal Regulations (C.F.R.) §§ 1308.11 through 1308.15. Substances are placed in their respective schedules based on whether they have a currently accepted medical use in treatment in the U.S., their relative abuse potential, and likelihood of causing dependence when abused. Examples of the drugs in each schedule are listed below. Schedule I Controlled Substances Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4- methylenedioxymethamphetamine ("Ecstasy"). Schedule II/IIN Controlled Substances (2/2N) Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence. Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone. Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®). Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital. 1 Schedule III/IIIN Controlled Substances (3/3N) Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.
    [Show full text]
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • Lidocaine Infusion for Analgesia MOA Pharmacology 1
    Lidocaine Infusion for Analgesia MOA Pharmacology 1. Attenuation of proinflammatory effects: Ø Hepatic metabolism with high extraction ratio; Ø Blocks polymorphonuclear granulocyte priming, plasma clearance is 10 ml/kg/min13 reducing release of cytokines & reactive oxygen species1 Ø Adjust dose based on hepatic function and 2. Diminish nociceptive signaling to central nervous system: blood flow Ø Inhibition of G-protein-mediated effects2 Ø Renal clearance of metabolites Ø Reduces sensitivity & activity of spinal cord neurons Ø Context-sensitive half-time after a 3-day infusion is (glycine and NMDA receptor mediated)3,4 ∼20–40 min Ø Clinical effect of lidocaine tends to exceed the 5 3. Reduces ectopic activity of injured afferent nerves duration of the infusion by 5.5 times the half-life, supporting the putative preventive analgesia effect14 Perioperative Use Dosing Ø IV local anesthetic infusions have been used safely for pain control in the perioperative setting since the early 1950’s6,7 Infusion: 2mg/kg/hr (range 1.5-3 mg/kg/hr) Ø Reduce pain, nausea, ileus duration, opioid requirement, Loading dose: 1.5mg/kg (range 1-2 mg/kg) and length of hospital stay Ø Strongly consider bolus to rapidly achieve therapeutic concentration, otherwise steady state 9-12 Evidence for Specific Surgeries: reached in 4-8 hr Ø Strong: Open & laparoscopic abdominal; Reduces Max dose: 4.5 mg/kg postoperative pain, speeds return of bowel function, Ø Consider total dose from other local anesthetics reduces PONV, reduces length of hospital stay (e.g. regional anesthesia, periarticular injections, & Ø Moderate: Open prostatectomy, thoracic procedures, local infiltration) ambulatory surgery, and major spine; Reduces Continuous infusions up to 3 mg/kg/hr have been postoperative pain and opioid consumption shown to be safe Ø Moderate: Breast; Prevention of chronic postsurgical pain Ø Reduce infusion rate in patients with impaired Ø No benefit: Total abdominal hysterectomy, total hip drug metabolism & clearance (i.e.
    [Show full text]
  • Highlights of This Issue
    THURSDAY, OCTOBER 4, 1973 WASHINGTON, D.C. HIGHLIGHTS OF THIS ISSUE This listing does not affect the legal status of any document published in this issue. Detailed table of contents appears inside. ECONOMIC STABILIZATION— CLC Phase IV pay and price regulations for certain reg­ istered, practical, and trained nurses (2 documents); effective 10—1—73....................... ........................ 27528, 27529 CLC allows Phase IV price increases for rubber tire and tube products; effective 10—8—73............................. ....... 27528 October 4, 1973— -Pages 27501-27574 METHAQUALONE— Justice Department classifies as Schedule II controlled substance; effective 10—4—73 27516 ARTISTS' PAINTS AND SUPPLIES— Consumer Product Safety Commission exempts from lead content restric­ tions; effective 12—3—73...-......... ........................................ 27514 DEFENSE CONTRACTS— Cost Amounting Standards Board extends disclosure statement filing requirements; effective 4— 1—74............................. ....................................... 27507 PUBLIC ASSISTANCE— HEW proposal on determin­ ing paternity of children receiving aid; comments by 1 1 -5 -7 3 ............................................ -. ............ : ........ 27530 SUGAR— USDA declares and reprorates 1973 quota deficits for Hawaii and Peru................... .................... ........................ 27509 USDA requires no proportionate shares for 1974 sugarbeet crop..--....................... ..............."...................... — 27510 PEANUTS— USDA proposes 1974
    [Show full text]
  • Local Anesthetic Toxicity: Prevention and Treatment
    Local Anesthetic Toxicity: Prevention and Treatment John W. Wolfe, M.D. Staff Anesthesiologist Indiana University School of Medicine Indianapolis, Indiana John F. Butterworth, M.D. Chairman, Department of Anesthesia Indiana University School of Medicine Indianapolis, Indiana LESSON OBJECTIVES dine, and the site of injection on peak Upon completion of this lesson, the reader local anesthetic concentrations in blood. should be able to: 6. Describe the mechanism of local anes- 1. List the signs and symptoms of local thetic central nervous system toxicity. anesthetic toxicity. 7. Identify the risk factors for local anes- 2. Discuss the concept of "maximum safe thetic toxicity. doses of a local anesthetic." 8. Plan the treatment of local anesthetic- 3. Describe methods for reducing the risk of induced cardiac arrhythmias and cardiac local anesthetic toxicity. arrest. 4. Explain the treatment of local anes- 9. Describe the mechanism of local anes- thetic-related neurologic symptoms and thetic cardiovascular toxicity. toxic side effects. 10. Explain the dosage and proposed mech- 5. Discuss the effects of epinephrine, cloni- anism of lipid emulsion therapy. Current Reviews for Nurse Anesthetists designates this lesson for 1 CE contact hour in Clinical pharmacology/therapeutics. Introduction Mechanism of Cardiac and central nervous system (CNS) toxic Local Anesthetic Toxicity side effects of local anesthetics are relatively rare but potentially catastrophic complications of local and Local anesthetics normally produce their desired regional anesthesia. Fortunately, the likelihood of a effects on peripheral nerves by binding and inhibit- local anesthetic toxic event can be reduced by ad- ing voltage-gated sodium channels in neural cell herence to good technique.
    [Show full text]
  • Drug Detection Time Window Chart
    Chesapeake Toxicology Resources Drug Detection Windows Updated as of December, 15th 2014 The length of time that the presence of drugs of abuse in the body can be detected is an important factor in drug screening. The chart below outlines approximate duration times. When interpreting the duration for the presence of drugs of abuse in the body, you must take into consideration variables including the body's metabolism, the subject's physical condition, overall body fluid balance, state of hydration and frequency of usage. Amphetamines Drug Name Metabolite Detection Window Prescription Names Amphetamine 3-5 Days Adderall, Adderall XR, Dexedrine, Spansule, DextroStat MDA 2-5 Days Tenamfetamine MDMA MDA 1-3 Days Adam, Ecstacy Methamphetamine Amphetamine 3-5 Days Desoxyn, Desoxyn Gradument Anti-epileptics Drug Name Metabolite Detection Window Prescription Names Gabapentin 1-5 Days Neurontin, Nupentin, Fanatrex, Gabarone, Gralise Pregablin 1-4 Days Lyrica CHESAPEAKE TOXICOLOGY RESOURCES- DRUG DETECTION TIMETABLE !1 Barbiturates Drug Name Metabolite Detection Window Prescription Names Amobarbital 2-10 Days Amytal, Amylobarbiton, Tuinal Butalbital 4-6 Days Axocet, Axotal, Bucet, Bupap, Butex Forte, Cephadyn, Dolgic, Esgic, Esgic-Plus, Fioricet, Fiorinal, Fiormor, Fiortal, Fortabs, Laniroif, Margesic, Marten-Tab, Medigesic, Phrenilin, Phrenilin Forte, Repan, Sedapap, Tencon, Triad Pentobarbital 2-10 Days Euthasol, Nembutal , Nembutal Sodium, Pentasol Phenobarbital Up to 16 days Antrocol, Barbidonna, Barbita, Bellacane, Bellatal, Bellergal-S, Chardonna-2,
    [Show full text]
  • Neurosteroid Metabolism in the Human Brain
    European Journal of Endocrinology (2001) 145 669±679 ISSN 0804-4643 REVIEW Neurosteroid metabolism in the human brain Birgit Stoffel-Wagner Department of Clinical Biochemistry, University of Bonn, 53127 Bonn, Germany (Correspondence should be addressed to Birgit Stoffel-Wagner, Institut fuÈr Klinische Biochemie, Universitaet Bonn, Sigmund-Freud-Strasse 25, D-53127 Bonn, Germany; Email: [email protected]) Abstract This review summarizes the current knowledge of the biosynthesis of neurosteroids in the human brain, the enzymes mediating these reactions, their localization and the putative effects of neurosteroids. Molecular biological and biochemical studies have now ®rmly established the presence of the steroidogenic enzymes cytochrome P450 cholesterol side-chain cleavage (P450SCC), aromatase, 5a-reductase, 3a-hydroxysteroid dehydrogenase and 17b-hydroxysteroid dehydrogenase in human brain. The functions attributed to speci®c neurosteroids include modulation of g-aminobutyric acid A (GABAA), N-methyl-d-aspartate (NMDA), nicotinic, muscarinic, serotonin (5-HT3), kainate, glycine and sigma receptors, neuroprotection and induction of neurite outgrowth, dendritic spines and synaptogenesis. The ®rst clinical investigations in humans produced evidence for an involvement of neuroactive steroids in conditions such as fatigue during pregnancy, premenstrual syndrome, post partum depression, catamenial epilepsy, depressive disorders and dementia disorders. Better knowledge of the biochemical pathways of neurosteroidogenesis and
    [Show full text]
  • Treatment Episode Data Set (TEDS) 2003 - 2013
    Treatment Episode Data Set (TEDS) 2003 - 2013 National Admissions to Substance Abuse Treatment Services DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration ACKNOWLEDGMENTS This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS), by Synectics for Management Decisions, Inc. (Synectics), Arlington, Virginia. Work by Synectics was performed under Task Order HHSS283200700048I/HHSS28342001T, Reference No. 283-07-4803 (Cathie Alderks, Task Order Officer). PUBLIC DOMAIN NOTICE All material appearing in this report is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, U.S. Department of Health and Human Services. RECOMMENDED CITATION Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2003-2013. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-75, HHS Publication No. (SMA) 15-4934. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015. ELECTRONIC ACCESS AND COPIES OF PUBLICATION This publication may be downloaded or ordered at store.samhsa.gov. Or call SAMHSA at 1-877-SAMHSA-7 (1-877-726-4727) (English and Español). ORIGINATING OFFICE Center for Behavioral Health Statistics and Quality Substance Abuse and Mental Health Services Administration 1 Choke Cherry Road, Room 2-1084 Rockville, Maryland 20857 December 2015 ii TABLE OF CONTENTS List of Tables ...................................................................................................................................v List of Figures ..............................................................................................................................
    [Show full text]
  • Drug Class Review on Skeletal Muscle Relaxants
    Drug Class Review on Skeletal Muscle Relaxants Final Report Update 2 May 2005 Original Report Date: April 2003 Update 1 Report Date: January 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2005 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically (see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 2 Drug Effectiveness Review Project TABLE OF CONTENTS Introduction........................................................................................................................4 Scope and
    [Show full text]